Loading…
BOOTS is a brand name for Pseudoephedrine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: A combination expectorant and decongestant for the relief of acute productive (chesty) cough, nasal congestion and congestion of the mucous membranes of the upper respiratory tract associated with the common cold.
Verbatim from this product's MHRA label. Tap a section to expand.
For oral administration.
Children 6 to 12 years:
Two 5ml spoonfuls three or four times a day. Not more than 4 doses should be given in any 24 hours. 3). Children of 6-12 years of age: not to be used for more than 5 days without the advice of a doctor. Parents and carers should seek medical attention if the child's condition deteriorates during treatment.
Warning:
Do not exceed the stated dose. Keep all medicines out of the sight and reach of children.
Guaifenesin The following side effects may be associated with the use of guaifenesin: Gastrointestinal disorders: nausea, vomiting, gastrointestinal discomfort. Immune system disorders: hypersensitivity reactions. Pseudoephedrine Cardiovascular disorders: tachycardia, palpitations, other cardiac dysrythmias.
Eye disorders:
Frequency unknown - Ischaemic optic neuropathy Gastrointestinal disorders: nausea and/or vomiting, dry mouth.
Frequency unknown:
Ischaemic colitis General disorders and administration site conditions: irritability, thirst, tolerance with dependence has been reported with prolonged administration of pseudoephedrine-containing preparations. Immune system disorders: hypersensitivity reactions, including cross- sensitivity that may occur with other sympathomimetics.
Musculoskeletal and connective tissue disorders: muscular weakness. Nervous system disorders: headache, giddiness, tremor, anxiety, restlessness, excitability, insomnia, hallucinations (particularly in children) and paranoid delusions.
4) Psychiatric disorders: sleep disturbance. Renal and urinary disorders: difficulty in micturition including urinary retention. Skin and subcutaneous tissue disorders: skin reactions including rash, sweating. Frequency unknown - Severe skin reactions, including acute generalized exanthematous pustulosis (AGEP).
Vascular disorders: hypertension. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4 Special warnings and special precautions for use Guaifenesin Ask a doctor before use if you suffer from a chronic cough, if you have asthma or are suffering from an acute asthma attack. Stop use and ask a healthcare professional if your cough lasts for more than 5 days, comes back, or is accompanied by a fever, rash, or persistent headache.
Do not take with a cough suppressant. Pseudoephedrine If any of the following occur, this medicine should be stopped Hallucinations Restlessness Sleep disturbances Caution in moderate to severe renal impairment. Pseudoephedrine should be used with caution when administered to patients taking antihypertensive agents, tricyclic antidepressants, other sympathomimetic agents such as decongestants, appetite suppressants and amphetamine-like psycho-stimulants.
The effects of a single dose on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment. Severe Skin reactions Severe skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with pseudoephedrine-containing products.
This acute pustular eruption may occur within the first 2 days of treatment, with fever, and numerous, small, mostly non-follicular pustules arising on a widespread oedematous erythema and mainly localized on the skin folds, trunk, and upper extremities.
Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema, or many small pustules are observed, administration of Boots Cough and Decongestant Syrup 6 Years + should be discontinued and appropriate measures taken if needed.
Ischaemic colitis Some cases of ischaemic colitis have been reported with pseudoephedrine. Pseudoephedrine should be discontinued and medical advice sought if sudden abdominal pain, rectal bleeding or other symptoms of ischaemic colitis develop Ischaemic optic neuropathy Cases of ischaemic optic neuropathy have been reported with pseudoephedrine.
Hypersensitivity to the active substances or any of the excipients or intolerance to other sympathomimetics. Severe renal impairment Severe acute or chronic kidney disease/renal failure Severe hypertension or uncontrolled hypertension Cardiovascular disease including hypertension and peripheral vascular disease.
5). 5). Not to be used in children under the age of 6 years.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Pseudoephedrine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Pseudoephedrine should be discontinued if sudden loss of vision or decreased visual acuity such as scotoma occurs. Posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS). 8). 3). Pseudoephedrine should be discontinued and immediate medical assistance sought if the following symptoms occur: sudden severe headache or thunderclap headache, nausea, vomiting, confusion, seizures and/or visual disturbances.
Most reported cases of PRES and RCVS resolved following discontinuation and appropriate treatment. Do not give with any other cough and cold medicine. If symptoms do not go away, talk to your pharmacist or doctor. Information about the ingredients in this medicine This medicine contains maltitol.
Patients with rare hereditary problems of fructose intolerance should not take this medicine. This medicine contains sorbitol. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.
The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly.